Value-based care is at the centre of industry discussions at the moment, not only advancing quality and equity in healthcare, but also accelerating innovation in care delivery.
As debate about the usefulness and ethics of generative artificial intelligence (AI) continues, the pharmaceutical industry needs to consider the advantages it can offer, especially for inc